Is Inhibrx Stock a good buy in 2024, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: INBX) stock is to Buy INBX stock.
Out of 1 analyst, 0 (0%) are recommending INBX as a Strong Buy, 1 (100%) are recommending INBX as a Buy, 0 (0%) are recommending INBX as a Hold, 0 (0%) are recommending INBX as a Sell, and 0 (0%) are recommending INBX as a Strong Sell.
What is INBX's revenue growth forecast for 2024-2024?
(NASDAQ: INBX) Inhibrx's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.
Inhibrx's revenue in 2024 is $1,800,000.
In 2024, INBX is forecast to generate $23,696,224 in revenue, with the lowest revenue forecast at $23,696,224 and the highest revenue forecast at $23,696,224.
What is INBX's forecast return on assets (ROA) for 2024-2024?
(NASDAQ: INBX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.76%.
What is INBX's Price Target?
According to 1 Wall Street analyst that have issued a 1 year INBX price target, the average INBX price target is $27.00, with the highest INBX stock price forecast at $27.00 and the lowest INBX stock price forecast at $27.00.
The Wall Street analyst predicted that Inhibrx's share price could fall to $27.00 by Nov 20, 2024. The average Inhibrx stock price prediction forecasts a potential downside of 21.33% from the current INBX share price of $34.32.
What is INBX's forecast return on equity (ROE) for 2024-2024?
(NASDAQ: INBX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.